Praxis Precision Medicines (PRAX) revenue
Only 2 fiscal years of revenue are on record here for Praxis Precision Medicines (PRAX); a history needs at least 3. Figures as of 18 Nov 2026, 10:37 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2024
- $8.55M
- Change on fiscal 2023
- +249.5%
- Fiscal years on record
- 22023–2024
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Not enough data
A history of revenue needs at least 3 fiscal years; 2 are on record here for Praxis Precision Medicines. Nothing is estimated to fill the gap. What is on record is in the table below.
Praxis Precision Medicines revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2024 | $8.55M | 249.5% up | |
| 2023 | $2.45M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Oscar Health OSCR | $11.70B | 2025 |
| TG Therapeutics TGTX | $616.29M | 2025 |
| Praxis Precision Medicines PRAX | $8.55M | 2024 |
| Twist Bioscience TWST | $459.43M | 2026 |
| Protagonist Therapeutics PTGX | $46.02M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Praxis Precision Medicines, figure by figure
- Praxis Precision Medicines market cap
- Praxis Precision Medicines earnings
- Praxis Precision Medicines earnings per share (EPS)
- Praxis Precision Medicines P/E ratio
- Praxis Precision Medicines P/S ratio
- Praxis Precision Medicines P/B ratio
- Praxis Precision Medicines free cash flow
- Praxis Precision Medicines operating margin
- Praxis Precision Medicines dividend
- Praxis Precision Medicines shares outstanding
- Praxis Precision Medicines total debt
- Praxis Precision Medicines cash on hand
- Praxis Precision Medicines total assets
- Praxis Precision Medicines return on equity (ROE)
- Praxis Precision Medicines return on invested capital (ROIC)
Praxis Precision Medicines (PRAX) overview: price, valuation and scorecardAll health care companies by market value
Praxis Precision Medicines revenue: questions and answers
How is Praxis Precision Medicines's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Praxis Precision Medicines it is on record here for 2 fiscal years, 2023 to 2024.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Praxis Precision Medicines (PRAX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/PRAX/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.